Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), further demonstrating its potential as a best-in-class obesity drug. In the 28-day ...

These tables have since been corrected in the article and PDF, and schizophrenia and insomnia have been removed from the list of mental health disorders more likely to occur in glucagon-like peptide-1 ...

For research papers The BMJ has fully open peer review. This means that accepted research papers published from early 2015 onwards usually have their prepublication history posted alongside them on ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment ... A survey of the US Food and Drug Administration Adverse Event Reporting System over 66 085 patients aged ...

pennmedicine.upenn.edu Background/aims Glucagon-like peptide-1 receptor (GLP-1R ... cohort of patients who initiated a new GLP-1R agonist was 1:3 age, gender, race, classes of active diabetes ...

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...